Clinical trials: Androgens
Metastatic Castration-resistant Prostate Cancer
A Study to Compare the Efficacy and Safety of BMS-986365 Versus the Investigator's Choice of Therapy in Participants With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to compare the efficacy and safety of BMS-986365 versus the investigator's choice of therapy in participants with Metastatic Castration-resistant Prostate Cancer.
- Trial name
- rechARge (NCT06764485)
- Testing
- BMS-986365, Enzalutamide, Abiraterone
- Where
- 227 sites in United States, Argentina and 24 more
- Volunteers
- 960 people
- Sponsor
- Celgene
Metastatic Castration-resistant Prostate Cancer
ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC
In this Phase 2 study, mCRPC patients with PSMA positive scans who progressed on prior ARTA and up to 2 lines of taxanes, and are naïve to lutetium Lu 177 vipivotide tetraxetan, will be enrolled.
- Trial name
- PRESERVE-006 (NCT05682443)
- Testing
- ONC-392 low, ONC-392 high, lutetium Lu 177 vipivotide tetraxetan
- Where
- 23 sites in United States
- Volunteers
- 148 people
- Sponsor
- OncoC4, Inc.
Cancer of the Breast, Breast Cancer
CYP17 Lyase and Androgen Receptor Inhibitor Treatment With Seviteronel Trial (INO-VT-464-006; NCT02580448)
The goal of this clinical study is to determine the safety, pharmacokinetics, pharmacodynamics and efficacy and activity of seviteronel, a lyase-selective inhibitor of CYP17, in patients with advanced breast cancer.
- Conditions
- Cancer of the Breast, Breast Cancer, Advanced Breast Cancer, Metastatic Breast Cancer
- Trial name
- CLARITY-01 (NCT02580448)
- Testing
- Seviteronel
- Where
- 36 sites in United States
- Volunteers
- 175 people
- Sponsor
- Innocrin Pharmaceutical
Metastatic Castration Resistant Prostate Cancer
A Study of AC176 for the Treatment of Metastatic Castration Resistant Prostate Cancer
This clinical trial is evaluating a drug called AC176 in participants with metastatic castration resistant prostate cancer (mCRPC) who have progressed on at least two prior systemic therapies.
- Trial name
- NCT05241613
- Testing
- AC176
- Where
- 5 sites in United States
- Volunteers
- 28 people
- Sponsor
- Accutar Biotechnology Inc
Prostate Cancer
A Comparative Study of Degarelix Three-month Depot in Three Different Dosing Regimens in Patients With Prostate Cancer
The rationale of the study was to evaluate different degarelix dosing regimens for a three-month interval that was to produce and maintain castration in prostate cancer patients through immediate and prolonged testosterone…
- Trial name
- NCT00116753
- Testing
- Degarelix
- Where
- 56 sites in United States, Belgium and 9 more
- Volunteers
- 460 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Neoadjuvant Study Investigating Degarelix in Patients Suffering From Prostate Cancer
The purpose of this phase 3B trial was to see how well a new trial drug (degarelix) works in terms of reducing the size of the prostate volume in prostate cancer patients who were scheduled to undergo subsequent radiotherapy for…
- Trial name
- NCT00833248
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 66 sites in United States, France and 5 more
- Volunteers
- 246 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Neoplasm
A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC
The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium [177Lu] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive…
- Trial name
- PSMACare (NCT05849298)
- Testing
- AAA617, AAA517, Piflufolastat F 18
- Where
- 31 sites in United States, Brazil and 9 more
- Volunteers
- 49 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer
Investigation of the Effect of Degarelix in Terms of Prostate Volume Reduction in Prostate Cancer Patients
This was a Phase 3b clinical study in prostate cancer patients which aimed to compare the current standard therapy of a gonadotrophin releasing hormone (GnRH) agonist, goserelin (3.6 mg; plus anti-androgen flare protection…
- Trial name
- NCT00884273
- Testing
- Degarelix, Goserelin, Bicalutamide
- Where
- 46 sites in Belgium, Denmark and 6 more
- Volunteers
- 182 people
- Sponsor
- Ferring Pharmaceuticals
Acne Vulgaris
An Evaluation of the Adrenal Suppression Potential and PK of CB-03-01 Cream in Pediatric Patients With Acne Vulgaris
This study is designed to determine the hypothalamic-pituitary-adrenal (HPA) axis suppression potential and pharmacokinetic (PK) properties of CB-03-01 Cream, 1%, applied every twelve hours for two weeks, in pediatric patients 9…
- Trial name
- NCT02720627
- Testing
- cortexolone 17α-propionate
- Where
- 10 sites in United States, Poland
- Volunteers
- 27 people
- Sponsor
- Cassiopea SpA
Prostate Cancer
Effect of Triptorelin (Decapeptyl®) 22.5 mg on Two Biomarkers in Patients With Advanced Prostate Cancer
The purpose of this study is to evaluate the effect of an initial hormonal treatment gonadotrophin-releasing hormone (GnRH Agonist) on 2 biomarkers (PCA3 and TMPRSS2-ERG), in patients with histologically confirmed and advanced…
- Trial name
- Triptocare (NCT01020448)
- Testing
- Triptorelin (Decapeptyl®)
- Where
- 59 sites in Belgium, Denmark and 8 more
- Volunteers
- 339 people
- Sponsor
- Ipsen
Prostate Cancer
Experiment to Assess Preferences for Novel Hormonal Therapy and Androgen-deprivation Therapy in Prostate Cancer Patients
The purpose of this study is to quantify the preferences for novel hormonal therapy (NHT) +/- androgen-deprivation therapy (ADT) vs ADT monotherapy among patients with non-metastatic hormone-sensitive prostate cancer (PC) in the…
- Trial name
- NCT06500741
- Testing
- No Intervention
- Where
- United States
- Volunteers
- 374 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Metastatic Hormonesensitive Prostate Cancer (mHSPC)
An Observational Study to Learn More About How Medicines That Block Male Hormones Are Used in People With Prostate Cancer in Australia
This is a retrospective, observational study looking at real-world prescription data in Australia. The study focuses on adult men with metastatic hormone-sensitive prostate cancer (mHSPC), a type of prostate cancer that has…
- Trial name
- TARA (NCT07223372)
- Where
- Australia
- Volunteers
- 1,000 people
- Sponsor
- Bayer
Hormone-Sensitive Prostate Cancer
Capivasertib+Abiraterone as Treatment for Patients With Metastatic Hormone-sensitive Prostate Cancer and PTEN Deficiency
This study will assess the efficacy and safety of capivasertib plus abiraterone (+prednisone/prednisolone) plus androgen deprivation therapy (ADT) versus placebo plus abiraterone (+prednisone/prednisolone) plus ADT in…
- Trial name
- CAPItello-281 (NCT04493853)
- Testing
- Capivasertib, Abiraterone Acetate
- Where
- 323 sites in United States, Argentina and 30 more
- Volunteers
- 1,012 people
- Sponsor
- AstraZeneca
Prostate Cancer
Intermittent Treatment With Degarelix of Patients Suffering From Prostate Cancer
The purpose of this uncontrolled, multi-center, open-label trial was to investigate the feasibility of using degarelix as intermittent androgen deprivation (IAD) therapy in the treatment of prostate cancer.
- Trial name
- NCT00801242
- Testing
- Degarelix 240 mg / 80 mg
- Where
- 52 sites in Belgium, France and 4 more
- Volunteers
- 220 people
- Sponsor
- Ferring Pharmaceuticals
Prostatic Cancer
Metabolic Changes in Prostate Cancer Patients With Androgen-ablation Therapy (AAT)
This is an observational, prospective, non-interventional and multi-centre study, to assess the impact of androgen ablation therapy in blood triglycerides, cholesterol and glucose, body fat distribution and fracture risk to ten…
- Trial name
- UROCOR (NCT01284608)
- Where
- 33 sites in Spain
- Volunteers
- 197 people
- Sponsor
- AstraZeneca
Metastatic Prostate Cancer
Phase II Sunitinib Prog Met AIPC
The purpose of this research study is to find out what effects (good and bad) Sutent has on you and your prostate cancer.
- Trial name
- NCT00599313
- Testing
- Sunitinib
- Where
- 45 sites in United States
- Volunteers
- 36 people
- Sponsor
- US Oncology Research
Prostate Cancer
A Degarelix Trial in Patients With Prostate Cancer
A phase III extension trial comparing the efficacy and safety of degarelix 3 month depot with the established therapy Zoladex 3 month implant in patients with prostate cancer.
- Trial name
- NCT01242748
- Testing
- Degarelix, Goserelin acetate
- Where
- 63 sites in United States, Belgium and 11 more
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Castrate-Resistant Prostate Cancer
Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway Inhibitor
This study is designed to assess the safety and tolerability of atezolizumab when given in combination with radium-223 dichloride in participants with metastatic CRPC who have progressed after treatment with an androgen pathway…
- Trial name
- NCT02814669
- Testing
- Atezolizumab, Radium-223 Dichloride
- Where
- 17 sites in United States
- Volunteers
- 45 people
- Sponsor
- Hoffmann-La Roche
Non-metastatic Prostate Cancer, Non-metastatic Castration-resistant Prostate Cancer
An Observational Study to Learn More About the Use of Androgen Receptor Inhibitors and How They Affect Men With Nonmetastatic Prostate Cancer in Routine Medical Care in the United States
This is an observational study in which data will be collected and studied from men with non-metastatic prostate cancer (nmPC) who received their usual treatment with 'androgen receptor inhibitors' (ARIs) including darolutamide…
- Trial name
- ARENA (NCT06204302)
- Testing
- Darolutamide (Nubeqa, BAY1841788), Enzalutamide, Apalutamide
- Where
- United States
- Volunteers
- 1,800 people
- Sponsor
- Bayer
Prostate Cancer
A Study of Galeterone Compared to Enzalutamide In Men Expressing Androgen Receptor Splice Variant-7 mRNA (AR-V7) Metastatic CRPC
The purpose of this study is to compare galeterone to enzalutamide in men expressing androgen receptor spice variant-7 mRNA (AR-V7) in metastatic (M1) castrate resistant prostate cancer (CRPC).
- Trial name
- ARMOR3-SV (NCT02438007)
- Testing
- Galeterone, Enzalutamide
- Where
- 117 sites in United States, Australia and 6 more
- Volunteers
- 953 people
- Sponsor
- LTN PHARMACEUTICALS, INC.